<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397889</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 15-0265</org_study_id>
    <nct_id>NCT02397889</nct_id>
  </id_info>
  <brief_title>Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)</brief_title>
  <official_title>Randomized Controlled Trial of Repeated-Dose Intravenous Ketamine for PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study new ways to treat post-traumatic stress disorder&#xD;
      (PTSD). Current treatments for PTSD do not work for everyone and it can take time to&#xD;
      determine whether a person responds to a chosen treatment. The purpose of this study is to&#xD;
      see whether ketamine, when given repeatedly intravenously can produce a quick and persistent&#xD;
      improvement in PTSD symptoms. At higher doses, ketamine has been used for many years as an&#xD;
      anesthetic for medical procedures, and at lower doses may be an effective treatment in&#xD;
      patients with major depression and PTSD. Ketamine given for PTSD is investigational, which&#xD;
      means that the FDA has not yet approved the drug for treating this condition. In this study,&#xD;
      the effects of ketamine will be compared to those of midazolam. Midazolam has similar acute&#xD;
      anesthetic effects compared to ketamine but has not been shown to treat or alleviate any&#xD;
      symptoms of PTSD. This makes midazolam an appropriate substance to gauge whether ketamine can&#xD;
      treat or alleviate PTSD symptoms thereby acting as what we call an active control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ketamine is an approved medication in several countries for the induction of general&#xD;
      anesthesia and for use as adjunct to other anesthetics. Intravenous ketamine is being&#xD;
      developed and tested for the treatment of posttraumatic stress disorder (PTSD).&#xD;
&#xD;
      All subjects will be administered the study medication by the study anesthesiologists and&#xD;
      under the direct supervision of the investigator or designee. On all dosing days, all&#xD;
      subjects must remain at the clinical site until at least 4 hours post-dose (or longer if&#xD;
      required for study procedures) and will be accompanied by a responsible adult when discharged&#xD;
      from the clinical site. The end of study will occur when the last subject in the trial&#xD;
      completes his/her last study assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 18, 2015</start_date>
  <completion_date type="Actual">January 27, 2020</completion_date>
  <primary_completion_date type="Actual">January 27, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)</measure>
    <time_frame>2 weeks after the first infusion</time_frame>
    <description>full range score from 0-80, with higher scores indicating greater PTSD symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Impact of Event Scale - Revised (IES-R)</measure>
    <time_frame>24 hours after the first drug infusion</time_frame>
    <description>full range score from 0-88, with higher scores indicating greater PTSD symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>24 hours after the first drug infusion</time_frame>
    <description>full range score from 0-60, with higher scores indicating greater depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>2 weeks after the first drug infusion</time_frame>
    <description>full range score from 0-60, with higher scores indicating greater depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depression Symptomatology - Self-Report (QIDS-SR)</measure>
    <time_frame>2 weeks after the first drug infusion</time_frame>
    <description>full range score from 0-27, with higher scores indicating greater depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Patient-Rated Inventory of Side Effects (PRISE)</measure>
    <time_frame>up to 21 weeks</time_frame>
    <description>All side effects listed in Adverse Event section.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Posttraumatic Stress Disorder (PTSD)</condition>
  <arm_group>
    <arm_group_label>Experimental ketamine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive 0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active control midazolam group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive 0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).</description>
    <arm_group_label>Experimental ketamine group</arm_group_label>
    <other_name>Generic only</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).</description>
    <arm_group_label>Active control midazolam group</arm_group_label>
    <other_name>Generic only</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women, 18-65 years of age;&#xD;
&#xD;
          -  Participants must have a level of understanding sufficient to agree to all tests and&#xD;
             examinations required by the protocol and must sign a written informed consent&#xD;
             document;&#xD;
&#xD;
          -  Participants must fulfill DSM-5 criteria for current civilian or combat-related PTSD&#xD;
&#xD;
          -  Women must be using a medically accepted reliable means of contraception (if using an&#xD;
             oral contraceptive medication, they must also be using a barrier contraceptive) or not&#xD;
             be of childbearing potential (i.e., surgically sterile, postmenopausal for at least&#xD;
             one year);&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test at screening and&#xD;
             prior to each intravenous infusion;&#xD;
&#xD;
          -  Participants must be able to identify a family member, physician, or friend (i.e.&#xD;
             someone who knows them well) who will participate in a Treatment Contract (and e.g.&#xD;
             contact the study physician on their behalf in case manic symptoms or suicidal&#xD;
             thoughts develop).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Women who plan to become pregnant, are pregnant or are breast-feeding&#xD;
&#xD;
          -  Serious, unstable medical illnesses such as hepatic, renal, gastroenterologic,&#xD;
             respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic&#xD;
             disease, including gastro-esophageal reflux disease, obstructive sleep apnea, history&#xD;
             of difficulty with airway management during previous anesthetics, ischemic heart&#xD;
             disease and uncontrolled hypertension, and history of severe head injury;&#xD;
&#xD;
          -  Clinically significant abnormal findings of laboratory parameters, physical&#xD;
             examination, or ECG;&#xD;
&#xD;
          -  Renal impairment, as reflected by a BUN &gt;20 mg/dL, and/or creatinin clearance of &gt;1.3&#xD;
             mg/dL;&#xD;
&#xD;
          -  Thyroid impairment, as reflected by TSH&gt; 4.2 mU/L Patients with uncorrected&#xD;
             hypothyroidism or hyperthyroidism;&#xD;
&#xD;
          -  Hormonal treatment (e.g., estrogen) started in the 3 months prior to the first&#xD;
             infusion day;&#xD;
&#xD;
          -  Use of evidence-based individual psychotherapy (such as prolonged exposure) during the&#xD;
             study;&#xD;
&#xD;
          -  History of autism, mental retardation, pervasive developmental disorders, or&#xD;
             Tourette's syndrome; History of one or more seizures without a clear and resolved&#xD;
             etiology;&#xD;
&#xD;
          -  History of (hypo)mania;&#xD;
&#xD;
          -  Past or current presence of psychotic symptoms, or diagnosis of a lifetime psychotic&#xD;
             disorder including schizophrenia or schizoaffective disorder;&#xD;
&#xD;
          -  Drug or alcohol abuse or dependence within the preceding 3 months&#xD;
&#xD;
          -  Previous recreational use of ketamine or PCP;&#xD;
&#xD;
          -  Current diagnosis of bulimia nervosa or anorexia nervosa;&#xD;
&#xD;
          -  Diagnosis of schizotypal or antisocial personality disorder&#xD;
&#xD;
          -  Patients judged clinically to be at serious and imminent suicidal or homicidal risk.&#xD;
&#xD;
          -  A blood pressure of one reading over 160/90 or two separate readings over 140/90 at&#xD;
             screen or baseline visits&#xD;
&#xD;
          -  Patients who report current treatment with a benzodiazepine, an opioid medication, or&#xD;
             a mood stabilizer (such as valproic acid or lithium) within 2 weeks prior to&#xD;
             randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana Feder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Depression and Anxiety Center (DAC)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <results_first_submitted>January 25, 2021</results_first_submitted>
  <results_first_submitted_qc>January 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 11, 2021</results_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Adriana Feder</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>posttraumatic stress disorder</keyword>
  <keyword>PTSD</keyword>
  <keyword>ketamine</keyword>
  <keyword>trauma</keyword>
  <keyword>treatment</keyword>
  <keyword>New York</keyword>
  <keyword>NYC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02397889/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental Ketamine Group</title>
          <description>0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).</description>
        </group>
        <group group_id="P2">
          <title>Active Control Midazolam Group</title>
          <description>0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental Ketamine Group</title>
          <description>0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).</description>
        </group>
        <group group_id="B2">
          <title>Active Control Midazolam Group</title>
          <description>0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.3" spread="13.8"/>
                    <measurement group_id="B2" value="38.5" spread="13.0"/>
                    <measurement group_id="B3" value="38.9" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Females</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Males</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current treatment with psychotropic medication</title>
          <description>Number of participants on current treatment with psychotropic medication</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinician Administered PTSD Scale (CAPS-5) score</title>
          <description>Clinician Administered PTSD Scale (CAPS-5) score, past month - full range score from 0-80, with higher scores indicating greater PTSD symptoms</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.9" spread="6.1"/>
                    <measurement group_id="B2" value="40.1" spread="5.9"/>
                    <measurement group_id="B3" value="40.9" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The Impact of Events Scale - Revised (IES-R)</title>
          <description>The Impact of Events Scale - Revised (IES-R) past 24 hours - full range score from 0-88, with higher scores indicating greater PTSD symptoms</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.4" spread="14.0"/>
                    <measurement group_id="B2" value="48.3" spread="20.1"/>
                    <measurement group_id="B3" value="44.8" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale (MADRS) score</title>
          <description>Montgomery Asberg Depression Rating Scale (MADRS) score, past week - full range score from 0-60, with higher scores indicating greater depressive symptoms</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.9" spread="6.8"/>
                    <measurement group_id="B2" value="26.9" spread="7.7"/>
                    <measurement group_id="B3" value="27.4" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale (MADRS) score</title>
          <description>Montgomery Asberg Depression Rating Scale (MADRS) score, past 24 hours</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" spread="6.6"/>
                    <measurement group_id="B2" value="25.3" spread="9.0"/>
                    <measurement group_id="B3" value="25.8" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of PTSD</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.1" spread="17.8"/>
                    <measurement group_id="B2" value="14.6" spread="7.8"/>
                    <measurement group_id="B3" value="14.9" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)</title>
        <description>full range score from 0-80, with higher scores indicating greater PTSD symptoms</description>
        <time_frame>2 weeks after the first infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Ketamine Group</title>
            <description>0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Active Control Midazolam Group</title>
            <description>0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)</title>
          <description>full range score from 0-80, with higher scores indicating greater PTSD symptoms</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="14.4"/>
                    <measurement group_id="O2" value="33.2" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Impact of Event Scale - Revised (IES-R)</title>
        <description>full range score from 0-88, with higher scores indicating greater PTSD symptoms</description>
        <time_frame>24 hours after the first drug infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Ketamine Group</title>
            <description>0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Active Control Midazolam Group</title>
            <description>0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>The Impact of Event Scale - Revised (IES-R)</title>
          <description>full range score from 0-88, with higher scores indicating greater PTSD symptoms</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" spread="15.2"/>
                    <measurement group_id="O2" value="24.8" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montgomery Asberg Depression Rating Scale (MADRS)</title>
        <description>full range score from 0-60, with higher scores indicating greater depressive symptoms</description>
        <time_frame>24 hours after the first drug infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Ketamine Group</title>
            <description>0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Active Control Midazolam Group</title>
            <description>0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale (MADRS)</title>
          <description>full range score from 0-60, with higher scores indicating greater depressive symptoms</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="9.6"/>
                    <measurement group_id="O2" value="17.1" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montgomery Asberg Depression Rating Scale (MADRS)</title>
        <description>full range score from 0-60, with higher scores indicating greater depressive symptoms</description>
        <time_frame>2 weeks after the first drug infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Ketamine Group</title>
            <description>0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Active Control Midazolam Group</title>
            <description>0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale (MADRS)</title>
          <description>full range score from 0-60, with higher scores indicating greater depressive symptoms</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="12.1"/>
                    <measurement group_id="O2" value="21.9" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quick Inventory of Depression Symptomatology - Self-Report (QIDS-SR)</title>
        <description>full range score from 0-27, with higher scores indicating greater depressive symptoms</description>
        <time_frame>2 weeks after the first drug infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Ketamine Group</title>
            <description>0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Active Control Midazolam Group</title>
            <description>0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Quick Inventory of Depression Symptomatology - Self-Report (QIDS-SR)</title>
          <description>full range score from 0-27, with higher scores indicating greater depressive symptoms</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="7.1"/>
                    <measurement group_id="O2" value="6.7" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Patient-Rated Inventory of Side Effects (PRISE)</title>
        <description>All side effects listed in Adverse Event section.</description>
        <time_frame>up to 21 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Ketamine Group</title>
            <description>0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Active Control Midazolam Group</title>
            <description>0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Patient-Rated Inventory of Side Effects (PRISE)</title>
          <description>All side effects listed in Adverse Event section.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 21 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental Ketamine Group</title>
          <description>0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).</description>
        </group>
        <group group_id="E2">
          <title>Active Control Midazolam Group</title>
          <description>0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty sleeping</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sleeping too much</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Poor concentration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Decreased energy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty urinating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Painful urination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Frequent urination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of sexual desire</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Trouble achieving orgasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Increased persipiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Exclusion of patients with comorbid psychotic, bipolar, or current alcohol or substance use disorders to protect against worsening of psychotic symptoms or abuse potential, which may limit generalizability of our findings to individuals with PTSD and these comorbid disorders.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Adriana Feder</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-659-9279</phone>
      <email>adriana.feder@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

